The NATION‐1907 trial has identified ‘Interferon/Epithelial‐mesenchymal transition (IFN/EMT) score’ signature and immune‐enriched tumour microenvironment phenotype to stratify for well responders who would benefit from neoadjuvant adebrelimab blockade, highlighting that anti‐PD‐L1 monotherapy may be sufficient in the immune “inflamed” patients. Here, CD274 is linked to neoplasm.